This is an FDA update from Vermillion/Aspira Labs. Recently, Vermillion has issued a letter explaining the FDA Safety Warning about recommending against using screening tests for ovarian cancer. In the letter, Vermillion discusses how OVA1, CA125 and ROMA should be used in determining appropriate screening tests for ovarian cancer and their technology in general.
Read the entire call to action letter here. Vermillion has helped sponsor Tell Every Amazing Lady®’s six educational PSA videos that include education about signs, symptoms and risks that can be viewed here.
